Chakraborty R, et al. - Researchers wanted to ascertain if, in the era of proteasome inhibitors and immunomodulatory drugs, the length of induction therapy (IT) in patients undergoing upfront autologous stem cell transplantation (ASCT) effected progression-free survival (PFS). Between 2007 and 2014, 596 patients who underwent ASCT at the Mayo Clinic were included. It was found that prolonging the duration of IT beyond 4 months did not impact survival in patients with newly diagnosed multiple myeloma who complete a single line of IT, followed by consolidation with ASCT.